Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05259085 · ClinicalTrials.gov registry record · Phase 1
Study of ALXN2050 in Participants With Hepatic Impairment
A Phase 1 study, sponsored by Alexion Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT05259085 is a Phase 1 study that was terminated before completion, run by Alexion Pharmaceuticals. The registered enrollment target is 26 participants.
The verdict
NCT05259085, a Phase 1 study, was terminated before completion, sponsored by Alexion Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
This study will investigate the impact of impaired hepatic function (IHF) on the plasma pharmacokinetics of ALXN2050 in order to provide dosing recommendations for future indications in individuals with varying degrees of IHF.
Interventions
- DRUG ALXN2050
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2022-04-07 |
| Est. Completion | 2024-08-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05259085
The ClinicalTrials.gov registry entry for NCT05259085 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ALXN2050 is the first listed.
NCT05259085 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05259085 about?
NCT05259085 is a clinical study titled "Study of ALXN2050 in Participants With Hepatic Impairment". This study will investigate the impact of impaired hepatic function (IHF) on the plasma pharmacokinetics of ALXN2050 in order to provide dosing recommendations for future indications in individuals with varying degrees of IHF.
What is the current status of trial NCT05259085?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2022-04-07. Estimated completion is 2024-08-12.
What interventions are being tested in trial NCT05259085?
The interventions under investigation include: ALXN2050 (DRUG).
Who is sponsoring clinical trial NCT05259085?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.